PL205057B1 - Zastosowanie koniugatu kwasu żółciowego albo soli kwasu żółciowego z kwasem tłuszczowym oraz zastosowanie kompozycji farmaceutycznej zawierającej taki koniugat - Google Patents
Zastosowanie koniugatu kwasu żółciowego albo soli kwasu żółciowego z kwasem tłuszczowym oraz zastosowanie kompozycji farmaceutycznej zawierającej taki koniugatInfo
- Publication number
- PL205057B1 PL205057B1 PL366585A PL36658502A PL205057B1 PL 205057 B1 PL205057 B1 PL 205057B1 PL 366585 A PL366585 A PL 366585A PL 36658502 A PL36658502 A PL 36658502A PL 205057 B1 PL205057 B1 PL 205057B1
- Authority
- PL
- Poland
- Prior art keywords
- acid
- bile
- fatty acid
- general formula
- compound
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 25
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 25
- 239000000194 fatty acid Substances 0.000 title claims abstract description 25
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 22
- 239000003613 bile acid Substances 0.000 title claims abstract description 21
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title claims abstract description 17
- 239000003833 bile salt Substances 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 19
- 208000010706 fatty liver disease Diseases 0.000 claims description 17
- 208000004930 Fatty Liver Diseases 0.000 claims description 14
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 13
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000003858 bile acid conjugate Substances 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- -1 bile acid fatty acid salt Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 6
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 230000000927 lithogenic effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Botany (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL142650A IL142650A (en) | 1998-04-08 | 2001-04-17 | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL366585A1 PL366585A1 (en) | 2005-02-07 |
| PL205057B1 true PL205057B1 (pl) | 2010-03-31 |
Family
ID=11075322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL366585A PL205057B1 (pl) | 2001-04-17 | 2002-04-15 | Zastosowanie koniugatu kwasu żółciowego albo soli kwasu żółciowego z kwasem tłuszczowym oraz zastosowanie kompozycji farmaceutycznej zawierającej taki koniugat |
| PL387458A PL211438B1 (pl) | 2001-04-17 | 2002-04-15 | Zastosowanie koniugatu kwasu żółciowego albo soli kwasu żółciowego z kwasem tłuszczowym oraz zastosowanie kompozycji farmaceutycznej zawierającej taki koniugat do obniżania poziomu cholesterolu we krwi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL387458A PL211438B1 (pl) | 2001-04-17 | 2002-04-15 | Zastosowanie koniugatu kwasu żółciowego albo soli kwasu żółciowego z kwasem tłuszczowym oraz zastosowanie kompozycji farmaceutycznej zawierającej taki koniugat do obniżania poziomu cholesterolu we krwi |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7501403B2 (enExample) |
| EP (2) | EP1379254B1 (enExample) |
| JP (1) | JP4324706B2 (enExample) |
| KR (1) | KR100883080B1 (enExample) |
| CN (1) | CN1259918C (enExample) |
| AT (2) | ATE432705T1 (enExample) |
| AU (2) | AU2002307771B2 (enExample) |
| BR (1) | BR0208924A (enExample) |
| CA (2) | CA2444266C (enExample) |
| CY (1) | CY1106853T1 (enExample) |
| CZ (2) | CZ300489B6 (enExample) |
| DE (2) | DE60232559D1 (enExample) |
| DK (2) | DK1790346T3 (enExample) |
| EA (1) | EA007565B1 (enExample) |
| ES (2) | ES2289137T3 (enExample) |
| HU (1) | HU230548B1 (enExample) |
| IL (1) | IL142650A (enExample) |
| MX (1) | MXPA03009553A (enExample) |
| NO (2) | NO333910B1 (enExample) |
| NZ (1) | NZ528868A (enExample) |
| PL (2) | PL205057B1 (enExample) |
| PT (2) | PT1790346E (enExample) |
| UA (1) | UA78699C2 (enExample) |
| WO (1) | WO2002083147A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142650A (en) | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| US8975246B2 (en) | 2001-04-17 | 2015-03-10 | Galmed Research And Development Ltd. | Bile acid or bile salt fatty acid conjugates |
| US20100311708A1 (en) * | 2007-07-25 | 2010-12-09 | Tarek Moustafa | Use of nor-bile acids in the treatment of arteriosclerosis |
| US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
| RS56054B1 (sr) * | 2009-01-12 | 2017-09-29 | Biokier Inc | Smeša i metod za lečenje dijabetesa |
| US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
| EP2391370B1 (en) | 2009-02-02 | 2015-06-03 | Galmed Research and Development Ltd. | Methods and compositions for treating alzheimer's disease |
| US20120202890A1 (en) | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| US9084826B2 (en) | 2012-05-01 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid conjugates of statin and FXR agonists; compositions and method of uses |
| CN103571617A (zh) * | 2012-07-26 | 2014-02-12 | 丰益(上海)生物技术研发中心有限公司 | 改进的动物油脂加工工艺 |
| US10702546B2 (en) | 2012-11-29 | 2020-07-07 | St Pharm Co., Ltd. | Bile acid oligomer conjugate for novel vesicular transport and use thereof |
| IL227890A0 (en) * | 2013-08-08 | 2014-01-30 | Galderm Therapeutics Ltd | Antiaging compounds containing bile acid and fatty acid conjugates |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| TR201909447T4 (tr) * | 2013-12-04 | 2019-07-22 | Galmed Res & Development Ltd | Aramkol tuzları. |
| US20170196891A1 (en) * | 2014-06-01 | 2017-07-13 | Galmed Research And Development Ltd. | Fatty acid bile acid conjugates for treatment of lipodystrophy |
| US10849911B2 (en) | 2015-06-10 | 2020-12-01 | Galmed Research And Development Ltd. | Low dose compositions of Aramachol salts |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CN116687850A (zh) | 2022-02-24 | 2023-09-05 | 甘莱制药有限公司 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3859437A (en) * | 1972-06-02 | 1975-01-07 | Intellectual Property Dev Corp | Reducing cholesterol levels |
| US3856953A (en) * | 1973-05-15 | 1974-12-24 | Intellectual Property Dev Corp | Method of treating fatty liver |
| IT1167479B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido chenodesossicolico |
| IT1167478B (it) * | 1981-07-24 | 1987-05-13 | Carlo Scolastico | Derivati dell'acido ursodesossicolico |
| JPS6164701A (ja) * | 1984-09-06 | 1986-04-03 | Meito Sangyo Kk | カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用 |
| DE3930696A1 (de) * | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5278320A (en) * | 1992-09-11 | 1994-01-11 | Merck & Co., Inc. | Cholesterol lowering compounds produced by directed biosynthesis |
| DE4432708A1 (de) * | 1994-09-14 | 1996-03-21 | Hoechst Ag | Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
| EP1027045A4 (en) * | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY |
| IL142650A (en) | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
| IL123998A (en) * | 1998-04-08 | 2004-09-27 | Galmed Int Ltd | Conjugates of bile salts and pharmaceutical preparations containing them |
| US6620821B2 (en) * | 2000-06-15 | 2003-09-16 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP2006306800A (ja) * | 2005-04-28 | 2006-11-09 | Kirin Brewery Co Ltd | ファルネソイドｘ受容体活性化剤 |
-
2001
- 2001-04-17 IL IL142650A patent/IL142650A/en active IP Right Grant
-
2002
- 2002-04-15 CZ CZ20032710A patent/CZ300489B6/cs not_active IP Right Cessation
- 2002-04-15 PT PT07002485T patent/PT1790346E/pt unknown
- 2002-04-15 EA EA200301017A patent/EA007565B1/ru not_active IP Right Cessation
- 2002-04-15 WO PCT/IL2002/000303 patent/WO2002083147A1/en not_active Ceased
- 2002-04-15 EP EP02761957A patent/EP1379254B1/en not_active Expired - Lifetime
- 2002-04-15 HU HU0400801A patent/HU230548B1/hu unknown
- 2002-04-15 DE DE60232559T patent/DE60232559D1/de not_active Expired - Lifetime
- 2002-04-15 CA CA2444266A patent/CA2444266C/en not_active Expired - Lifetime
- 2002-04-15 PL PL366585A patent/PL205057B1/pl unknown
- 2002-04-15 US US10/474,032 patent/US7501403B2/en not_active Expired - Lifetime
- 2002-04-15 NZ NZ528868A patent/NZ528868A/en not_active IP Right Cessation
- 2002-04-15 CZ CZ2008296A patent/CZ309042B6/cs not_active IP Right Cessation
- 2002-04-15 CN CNB028081870A patent/CN1259918C/zh not_active Expired - Lifetime
- 2002-04-15 CA CA2703688A patent/CA2703688C/en not_active Expired - Lifetime
- 2002-04-15 ES ES02761957T patent/ES2289137T3/es not_active Expired - Lifetime
- 2002-04-15 AT AT07002485T patent/ATE432705T1/de not_active IP Right Cessation
- 2002-04-15 ES ES07002485T patent/ES2328966T3/es not_active Expired - Lifetime
- 2002-04-15 MX MXPA03009553A patent/MXPA03009553A/es active IP Right Grant
- 2002-04-15 UA UA2003109404A patent/UA78699C2/uk unknown
- 2002-04-15 DK DK07002485T patent/DK1790346T3/da active
- 2002-04-15 AU AU2002307771A patent/AU2002307771B2/en not_active Expired
- 2002-04-15 DE DE60220775T patent/DE60220775T2/de not_active Expired - Lifetime
- 2002-04-15 DK DK02761957T patent/DK1379254T3/da active
- 2002-04-15 JP JP2002580951A patent/JP4324706B2/ja not_active Expired - Lifetime
- 2002-04-15 PL PL387458A patent/PL211438B1/pl unknown
- 2002-04-15 PT PT02761957T patent/PT1379254E/pt unknown
- 2002-04-15 AT AT02761957T patent/ATE365044T1/de active
- 2002-04-15 EP EP07002485A patent/EP1790346B1/en not_active Expired - Lifetime
- 2002-04-15 KR KR1020037013339A patent/KR100883080B1/ko not_active Expired - Lifetime
- 2002-04-15 BR BR0208924-6A patent/BR0208924A/pt not_active Application Discontinuation
-
2003
- 2003-10-15 NO NO20034609A patent/NO333910B1/no not_active IP Right Cessation
-
2007
- 2007-01-19 AU AU2007200191A patent/AU2007200191B2/en not_active Expired
- 2007-09-07 CY CY20071101160T patent/CY1106853T1/el unknown
-
2009
- 2009-01-28 US US12/361,291 patent/US8110564B2/en not_active Expired - Lifetime
-
2013
- 2013-09-10 NO NO20131219A patent/NO335087B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL205057B1 (pl) | Zastosowanie koniugatu kwasu żółciowego albo soli kwasu żółciowego z kwasem tłuszczowym oraz zastosowanie kompozycji farmaceutycznej zawierającej taki koniugat | |
| KR101358078B1 (ko) | 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물 | |
| Okediran et al. | Alterations in the lipid profile and liver enzymes of rats treated with monosodium glutamate | |
| JP2009542226A (ja) | 強化乳児用調乳 | |
| AU2002307771A1 (en) | Use of bile acid or bile salt fatty acid conjugates | |
| US8975246B2 (en) | Bile acid or bile salt fatty acid conjugates | |
| KR20030036898A (ko) | 지질 대사 개선용 조성물 | |
| US20240424066A1 (en) | Chondroprotective Nutraceutical Composition and Method of Using Same | |
| ES2317309T3 (es) | Complemento alimentario para animales de cria. | |
| AU2008249537A1 (en) | Use of bile acid or bile salt fatty acid conjugates | |
| ITMI991458A1 (it) | Biopolimeri non digeribili e/o non assorbibili chimicamente derivatizzati quali antagonisti competitivi dell'assorbimento intestinale di nut | |
| ES2239541B1 (es) | Potenciacion de las acciones anabolizantes de los compuestos esteroideos por suplementos de arginina y/o sus precursores. | |
| WO2013132092A1 (en) | Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat | |
| PL207684B1 (pl) | Preparat dietetyczny wspomagający odchudzanie |